ROCHE-BO16934



A randomized, open-label study of the effect of different doses of pertuzumab on treatment response in patients with metastatic breast cancer with low HER2 expression
Pertuzumab
BO16934
malignant neoplasm of breast
Phase 2
 
January 2015